Results 61 to 70 of about 688 (142)

sj-docx-1-taw-10.1177_20420986221135931 – Supplemental material for Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study

, 2022
Supplemental material, sj-docx-1-taw-10.1177_20420986221135931 for Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study by Beth L. Nordstrom, Bin Cai, Fabio De Gregorio, Lu Ban, Kathy H. Fraeman, Yuki Yoshida
Yuki Yoshida (2354824), Trevor Gibbs (40360), Beth L. Nordstrom (9338778), Lu Ban (139640), Kathy H. Fraeman (9338775), Bin Cai (110662), Fabio De Gregorio (11259791)   +6 more
core   +1 more source

sj-tiff-2-taw-10.1177_20420986221135931 – Supplemental material for Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study

, 2022
Supplemental material, sj-tiff-2-taw-10.1177_20420986221135931 for Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study by Beth L. Nordstrom, Bin Cai, Fabio De Gregorio, Lu Ban, Kathy H. Fraeman, Yuki Yoshida
Yuki Yoshida (2354824), Trevor Gibbs (40360), Beth L. Nordstrom (9338778), Lu Ban (139640), Kathy H. Fraeman (9338775), Bin Cai (110662), Fabio De Gregorio (11259791)   +6 more
core   +1 more source

sj-tif-4-taw-10.1177_20420986221135931 – Supplemental material for Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study

, 2022
Supplemental material, sj-tif-4-taw-10.1177_20420986221135931 for Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study by Beth L. Nordstrom, Bin Cai, Fabio De Gregorio, Lu Ban, Kathy H.
Yuki Yoshida (2354824), Trevor Gibbs (40360), Beth L. Nordstrom (9338778), Lu Ban (139640), Kathy H. Fraeman (9338775), Bin Cai (110662), Fabio De Gregorio (11259791)   +6 more
core   +1 more source

Treating and Managing Urinary Incontinence: Evolving and Potential Multicomponent Medical and Lifestyle Interventions

Research and Reports in Urology, 2023
Rayan Mohamed-Ahmed, Annika Taithongchai, Ana Sofia da Silva, Dudley Robinson, Linda Cardozo Department of Urogynaecology, King’s College Hospital, London, UKCorrespondence: Rayan Mohamed-Ahmed, Email r.mohamed-ahmed@nhs.netAbstract: Incontinence is ...
Mohamed-Ahmed R, Taithongchai A, da Silva AS, Robinson D, Cardozo L   +4 more
doaj  

sj-tif-3-taw-10.1177_20420986221135931 – Supplemental material for Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study

, 2022
Supplemental material, sj-tif-3-taw-10.1177_20420986221135931 for Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study by Beth L. Nordstrom, Bin Cai, Fabio De Gregorio, Lu Ban, Kathy H.
Yuki Yoshida (2354824), Trevor Gibbs (40360), Beth L. Nordstrom (9338778), Lu Ban (139640), Kathy H. Fraeman (9338775), Bin Cai (110662), Fabio De Gregorio (11259791)   +6 more
core   +1 more source

Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract and tolerability in postmenopausal women

, 2005
OBJECTIVE: To compare ospemifene and raloxifene regarding their effects on hormones, lipids, genital tract, and tolerability in postmenopausal women. DESIGN: A randomized, double-blind study in which 118 healthy postmenopausal women received 30 (n = 29),
DeGregorio, M W, Erkkola, R, Ylikorkala, O, Tuimala, R, Vihtamaki, T, Komi, J, Kivinen, S, Vihko, K, Voipio, S, Lankinen, K S, Härkönen, Pirkko   +10 more
core   +1 more source

Treatment patterns for genitourinary syndrome of menopause: a TriNetX analysis

The Canadian Journal of Urology
Background: Genitourinary syndrome of menopause (GSM) is a highly prevalent, underdiagnosed condition that can significantly impair quality of life (QoL).
Anushka Ghosh, Maria J. D’Amico, Yash B. Shah, Whitney R. Smith, Mihir S. Shah, Costas D. Lallas, Alana M. Murphy   +6 more
doaj   +1 more source

The effect of renal and hepatic impairment on the pharmacokinetics of ospemifene, a tissue-selective estrogen agonist/antagonist

, 2015
Ospemifene is a nonestrogen tissue-selective estrogen agonist/antagonist approved to treat moderate to severe dyspareunia due to vulvar and vaginal atrophy in postmenopausal women.
Wajima, Toshihiro, Graham, Shelli, Marbury, Thomas C, Preston, Richard A   +3 more
core   +1 more source

Design, synthesis, anti-proliferative evaluation and docking studies of 1H-1,2,3-triazole tethered ospemifene–isatin conjugates as selective estrogen receptor modulators

, 2018
A library of 1H-1,2,3-triazole-tethered ospemifene–isatin and ospemifene–spiroisatin conjugates have been synthesized and evaluated for their anti-proliferative activities against MCF-7 and MDA-MB-231 cell lines.
Sumit Kumar, Gabriella Palma, Ashona Singh-Pillay, Vipan Kumar, Liang Gu, Mandeep Kaur, Parvesh Singh   +6 more
core   +1 more source

Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study [PDF]

, 2017
Cervical cancer (CC) treatments impact quality of life (QoL) and sexual function (SF) of survivors. Treatment options to reduce sexual dysfunction are limited.
Giuseppe Bifulco, MORRA, ILARIA, Pierluigi Giampaolino, DE ROSA, NICOLETTA, GIAMPAOLINO, PIERLUIGI, BIFULCO, GIUSEPPE, Nicoletta De Rosa, Giada Lavitola, NAPPI, CARMINE, Ilaria Morra, Carmine Nappi, Lavitola, Giada   +11 more
core   +1 more source